➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Johnson and Johnson
AstraZeneca
Moodys
Dow

Last Updated: January 21, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for MGB-BP-3

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for MGB-BP-3?

MGB-BP-3 is an investigational drug.

There have been 4 clinical trials for MGB-BP-3. The most recent clinical trial was a Phase 1 trial, which was initiated on January 1st 2019.

The most common disease conditions in clinical trials are Vomiting, Postoperative Nausea and Vomiting, and Nausea. The leading clinical trial sponsors are MGB Biopharma Limited, Analytical Services International Limited, and Viapath.

There is one US patent protecting this investigational drug and thirteen international patents.

Recent Clinical Trials for MGB-BP-3
TitleSponsorPhase
Study to Assess Safety, Tolerability and Efficacy of Incremental Doses of MGB-BP-3 in Patients With CDADSyneos HealthPhase 2
Study to Assess Safety, Tolerability and Efficacy of Incremental Doses of MGB-BP-3 in Patients With CDADMGB Biopharma LimitedPhase 2
Effect of PNPLA3, TM6SF2 and MBOAT7 Genetic Variants on Non-alcoholic Fatty Liver Disease Therapeutic Outcome.Federico II UniversityN/A

See all MGB-BP-3 clinical trials

Clinical Trial Summary for MGB-BP-3

Top disease conditions for MGB-BP-3
Top clinical trial sponsors for MGB-BP-3

See all MGB-BP-3 clinical trials

International Patents for MGB-BP-3

Drugname Country Document Number Estimated Expiration Related US Patent
MGB-BP-3 Canada CA2664847 2026-09-30   Start Trial
MGB-BP-3 China CN101589024 2026-09-30   Start Trial
MGB-BP-3 Denmark DK2066627 2026-09-30   Start Trial
MGB-BP-3 European Patent Office EP2066627 2026-09-30   Start Trial
MGB-BP-3 Spain ES2443720 2026-09-30   Start Trial
MGB-BP-3 United Kingdom GB0619325 2026-09-30   Start Trial
MGB-BP-3 United Kingdom GB0906908 2026-09-30   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Johnson and Johnson
AstraZeneca
Moodys
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.